Loncar Cancer Immunothera... (CNCR)
NASDAQ: CNCR
· Real-Time Price · USD
8.89
-0.03 (-0.34%)
At close: May 20, 2025, 3:55 PM
8.87
-0.22%
After-hours: May 20, 2025, 04:05 PM EDT
-0.34% (1D)
| Bid | 7.94 |
| Market Cap | 7.83M |
| AUM | 12.73M |
| NAV | 13.68 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 881K |
| Inception Date | Oct 14, 2015 |
| Ask | 8.92 |
| Volume | 1.53K |
| Open | 8.89 |
| Previous Close | 8.92 |
| Day's Range | 8.89 - 8.91 |
| 52-Week Range | 7.88 - 16.27 |
| Holdings | 31 |
| Expense Ratio | 0.79% |
About CNCR
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Asset Class Equity
Ticker Symbol CNCR
Inception Date Oct 14, 2015
Provider Other
Website Fund Home Page
Exchange NASDAQ
Top 10 Holdings 34.43% of assets
| Name | Symbol | Weight |
|---|---|---|
| Instil Bio, Inc. | TIL | 3.59% |
| Replimune Group, Inc... | REPL | 3.54% |
| Iovance Biotherapeut... | IOVA | 3.47% |
| Zymeworks Inc. | ZYME | 3.45% |
| Argenx Se | ARGX | 3.42% |
| Genmab A/s | GMAB | 3.42% |
| Astrazeneca PLC | AZN | 3.39% |
| Bristol-myers Squibb... | BMY | 3.39% |
| Crispr Therapeutics ... | CRSP | 3.39% |
| Merck & Co., Inc. | MRK | 3.37% |
Dividends Dividend Yield 7.75%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 29, 2021 | $1.8533 | Dec 31, 2021 |
| Dec 30, 2020 | $0.2881 | Jan 4, 2021 |
| Dec 28, 2017 | $0.3502 | Jan 2, 2018 |
| Dec 29, 2015 | $0.1060 | Jan 4, 2016 |
